ATLN Atlantic International Corp. logo

ATLN Atlantic International Corp.

Healthcare
$1.42+5.19%ClosedMarket Cap: $112.7M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

PEG

P/B

-2.43

P/S

0.26

EV/EBITDA

-3.46

DCF Value

$-6.26

FCF Yield

-4.0%

Div Yield

0.0%

Margins & Returns

Gross Margin

10.6%

Operating Margin

-11.5%

Net Margin

-13.6%

ROE

274.3%

ROA

-52.5%

ROIC

-801.2%

Financials

View All
PeriodRevenueNet IncomeEPS
Q4 null$120.0M$-27.1M$
FY null$435.9M$-59.4M$
Q3 null$110.1M$-10.8M$
Q2 null$102.9M$-10.7M$

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$—

Target (Median)

$—

Target Range

$— - $—

0 Strong Buy1 Buy0 Hold0 Sell0 Strong Sell

Trading Activity

Insider Trades

View All
PFEFFER DAVIDdirector
SellMon Mar 16
Franke Guus Paul Wilhelmdirector, 10 percent owner:
SellTue Feb 10
Murphy Kevin Jamesofficer: Chief Financial Officer
SellThu Feb 05
Tenore Michaelofficer: General Counsel
SellWed Jan 07
Tenore Michaelofficer: General Counsel
SellWed Jan 07

Company Info

Sector

Healthcare

Industry

Medical - Diagnostics & Research

Country

US

Exchange

Beta

0.72

As of June 18, 2024, Atlantic International Corp. was acquired by Lyneer Investments, LLC, in a reverse merger transaction. Atlantic International Corp. operates as a life sciences instrumentation and research services company. It focuses on development of scientific assets and novel intellectual property across multiple omics fields. The company's True Single Molecule Sequencing technology (tSMS) platform offers a single molecule solution for DNA and RNA sequencing through detection of nucleic acids to researchers for analyzing many billions of single molecules in a single experiment and generate accurate and reproducible data. It provides solutions for various applications, such as biomarker discovery and diagnostic assay developments, including laboratories associated with universities, scientific research centers, government institutions, and biotechnology and pharmaceutical companies. In addition, the company has research and development agreement with U.S. Department of Justice's Federal Bureau of Investigation to evaluate and determine the forensic capabilities of direct RNA sequencing using tSMS platform; and Weizmann Institute of Science for developed and applied innovative single-molecule technologies. The company was formerly known as SeqLL Inc. and changed its name to Atlantic International Corp. in June 2024. The company was founded in 2013 and is headquartered in Billerica, Massachusetts.

Peers